Accro Bioscience and Fosun Pharma ink agreement for TYK2/JAK1 Inhibitor in Greater China
Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
Merger is expected to streamline operations and provide unified management focus, driving efficiency and strategic alignment
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
The $700 million project is part of Roche’s $50 billion investment in US manufacturing, infrastructure and R&D
Astaxanthin is a powerful antioxidant and red-orange carotenoid pigment found in various aquatic organisms
The company has improved access to quality healthcare for seniors across both urban and rural areas
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
Subscribe To Our Newsletter & Stay Updated